Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CALCRLCHRM1CHRM2CHRM3F2RMAOAMAOBMAP2K1MAP2K2NTRK1NTRK2NTRK3OPRD1OPRK1OPRM1P2RY12PKLRSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASLC18A2SLC6A2SLC6A3TLR7TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8dacAdacBdacCfolAftsImrcAmrcBmrdApolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmB1rpmB2rpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmHrpmIrpmJrpmJ2rpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsR1rpsR2rpsSrpsTrpsUrpsZykgMykgO
The experimentally established mechanism targets of Androsterone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | G6PD | P11413 | 6/20 | 0.90 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.90 |
| ▸ | LMNA | P02545 | 3/20 | 0.90 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.90 |
| ▸ | MEN1 | O00255 | 3/20 | 0.90 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.90 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.90 |
| ▸ | SHBG | P04278 | 2/20 | 0.90 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.90 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.90 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.90 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.90 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.90 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.90 |
| ▸ | TSHR | P16473 | 1/20 | 0.90 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.90 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.90 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Androsterone SCHEMBL17165679 | 1.00 | G6PD (0.90) | G6PDGPBAR1LMNACYP3A4MEN1 | |
| Androsterone SCHEMBL235686 | 1.00 | G6PD (0.90) | G6PDGPBAR1LMNACYP3A4MEN1 | |
| Androsterone SCHEMBL17165674 | 1.00 | G6PD (0.90) | G6PDGPBAR1LMNACYP3A4MEN1 | |
| Androsterone SCHEMBL7989333 | 0.99 | G6PD (0.88) | G6PDGPBAR1LMNACYP3A4MEN1 | |
| Androsterone SCHEMBL1570817 | 0.99 | G6PD (0.88) | G6PDGPBAR1LMNACYP3A4MEN1 | |
| Androsterone SCHEMBL7996607 | 0.99 | G6PD (0.88) | G6PDGPBAR1LMNACYP3A4MEN1 | |
| Androsterone SCHEMBL23031469 | 0.95 | G6PD (1.00) | G6PDGPBAR1LMNACYP3A4MEN1 | |
| Androsterone SCHEMBL19750468 | 0.95 | G6PD (1.00) | G6PDGPBAR1LMNACYP3A4MEN1 | |
| Androsterone SCHEMBL269982 | 0.95 | G6PD (1.00) | G6PDGPBAR1LMNACYP3A4MEN1 | |
| Androsterone SCHEMBL15426610 | 0.95 | G6PD (1.00) | G6PDGPBAR1LMNACYP3A4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 222 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049082-A1 | AMIDO PYRIDO[3,4-B]INDOLE-1,4-DIONE COMPOUNDS FOR TREATMENT OF PORPHYRIAS | PORTAL THERAPEUTICS INC (US) | 2026-02-19 | — | — | US | claimed |
| US-20250199014-A1 | METABOLITE BIOMARKERS FOR DISEASES ASSOCIATED WITH THE CONTACT ACTIVATION SYSTEM | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-06-19 | — | — | US | claimed |
| CN-119517408-A | Method for establishing death prediction model of new-onset type 2 diabetes and application | 中南大学湘雅二医院 | 2025-02-25 | — | — | CN | claimed |
| CN-115128257-B | Metabolism marker for predicting liver cancer incidence risk and application thereof | 南京医科大学 | 2025-02-18 | — | — | CN | claimed |
| US-12188948-B2 | Metabolite biomarkers for diseases associated with the contact activation system | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-01-07 | — | — | US | claimed |
| CN-109716137-B | Metabolite biomarkers for diseases associated with contact activation systems | 武田药品工业株式会社 | 2023-07-21 | — | — | CN | claimed |
| CN-116381073-A | Application of biomarker in preparation of lung cancer detection reagent and method | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 2023-07-04 | — | — | CN | claimed |
| US-20230194554-A1 | USE OF BIOMARKER IN PREPARATION OF LUNG CANCER DETECTION REAGENT AND RELATED METHOD | SUN YAT-SEN UNIVERSITY CANCER CENTER (THE AFFILIATED CANCER HOSPITAL OF SUN YAT-SEN UNIVERSITY, THE CANCER RESEARCH INSTITUTE OF SUN YAT-SEN UNIVERSITY) (CN) | 2023-06-22 | — | — | US | claimed |
| WO-2023083020-A1 | USE OF SERUM METABOLIC MARKER FOR DETECTING EGFR MUTATION AND DETECTION SYSTEM | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 2023-05-19 | — | — | WO | claimed |
| CN-115575553-A | Application of serum metabolic marker as EGFR mutation detection and detection system | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 2023-01-06 | — | — | CN | claimed |
| US-20100273207-A1 | Methods for Diagnosis of Sepsis and Risk of Death | LANGLEY RAYMOND | 2010-10-28 | — | — | US | claimed |
| EP-1555025-A2 | Use of dehydroepiandrosterone analogs for the treatment of asthma | EAST CAROLINA UNIVERSITY (US) | 2005-07-20 | — | — | EP | claimed |
| EP-0977576-B1 | OSTEOBLAST-PROMOTING PHARMACEUTICAL COMPOSITION COMPRISING A CARNITINE COMPOUND AND DHEA OR DHEA-S | SIGMA TAU IND FARMACEUTI (IT) | 2004-06-23 | — | — | EP | claimed |
| US-6710059-B1 | ADMINISTERING A SELECTIVE ESTROGEN RECEPTOR MODULATOR IN COMBINATION WITH A SEX STEROID PRECURSOR | ENDORECHERCHE, INC. (CA) | 2004-03-23 | — | — | US | claimed |
| US-20040034000-A1 | Methods of treating and/or suppressing insulin resistance | ENDORECHERCHE, INC. | 2004-02-19 | — | — | US | claimed |
| JP-2002522389-A | — | — | 2002-07-23 | — | — | JP | claimed |
| EP-1102590-A1 | USE OF A NK-1 RECEPTOR ANTAGONIST FOR TREATING OR PREVENTING ABNORMAL BONE RESORPTION | MERCK SHARP & DOHME LTD. (GB) | 2001-05-30 | — | — | EP | claimed |
| WO-2000007598-A1 | USE OF A NK-1 RECEPTOR ANTAGONIST FOR TREATING OR PREVENTING ABNORMAL BONE RESORPTION | MERCK SHARP & DOHME LIMITED (GB) | 2000-02-17 | — | — | WO | claimed |
| EP-0977576-A1 | OSTEOBLAST-PROMOTING PHARMACEUTICAL COMPOSITION COMPRISING A CARNITINE COMPOUND AND DHEA OR DHEA-S | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2000-02-09 | — | — | EP | claimed |
| WO-1998046233-A1 | OSTEOBLAST-PROMOTING PHARMACEUTICAL COMPOSITION COMPRISING A CARNITINE COMPOUND AND DHEA OR DHEA-S | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1998-10-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034000-A1 | Methods of treating and/or suppressing insulin resistance | SHBG, HSD17B11, HSD17B3 | G6PD 298/4885GPBAR1 110/4885LMNA 3335/4885 |
| US-20260049082-A1 | AMIDO PYRIDO[3,4-B]INDOLE-1,4-DIONE COMPOUNDS FOR TREATMENT OF PORPHYRIAS | CYC1, HMOX1, ABCC3 | G6PD 180/4885GPBAR1 269/4885LMNA 2623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.